Treats asthma. ANDA 205107, held by Amneal Pharmaceuticals. Montelukast Sodium.
As of Nov 21, 2026, ANDA 205107 (Montelukast Sodium), held by Amneal Pharmaceuticals, was first approved by FDA on Sep 4, 2020, with 1 approved supplement and 0 published complete response letters.
Montelukast sodium chewable tablets are a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 2 years of age and older. Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older. Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older and perennial allergic rhinitis (PAR) in patients 2 years of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies. Limitations of Use: Not indicated to treat an acute asthma attack. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 4, 2020 | Original application | Approved | None posted |
| Montelukast SodiumEQ 4MG BASE · tablet, chewable;oral | Montelukast Sodium | Discontinued |
| Montelukast SodiumEQ 5MG BASE · tablet, chewable;oral | Montelukast Sodium | Discontinued |
| Apr 16, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 4, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters